As the Senior Global Director of Medical Affairs at Merck, Jose Atwan plays a pivotal role in shaping the future of oncology treatment through his leadership in biomarker and companion diagnostic strategies. With a specialized focus on genitourinary cancers, including renal cell carcinoma (RCC), urothelial...
As the Senior Global Director of Medical Affairs at Merck, Jose Atwan plays a pivotal role in shaping the future of oncology treatment through his leadership in biomarker and companion diagnostic strategies. With a specialized focus on genitourinary cancers, including renal cell carcinoma (RCC), urothelial carcinoma, and prostate cancer, Jose is at the forefront of integrating innovative diagnostics into clinical practice. His strategic oversight extends to a significant alliance with AstraZeneca, where he collaborates on advancing diagnostic solutions for prostate and ovarian cancers, ensuring that patients have access to the most effective therapies based on their unique biomarker profiles.
Jose’s extensive experience, spanning over nine years in the pharmaceutical industry, equips him with a deep understanding of the complexities involved in biomarker development and implementation. He excels in planning and executing strategies that facilitate the adoption of new biomarkers across diverse global markets, enhancing awareness and access to cutting-edge diagnostics. His ability to collaborate cross-functionally with research and development (R&D), regulatory affairs, and commercial teams ensures a cohesive approach to medical education and the dissemination of critical insights.
In addition to his strategic leadership, Jose is adept in customer relationship management (CRM) and continuing medical education (CME), fostering strong partnerships with healthcare professionals to drive the integration of biomarkers into clinical workflows. His commitment to advancing medical science is reflected in his contributions to publications and his role in cross-functional coordination, where he leads teams to achieve shared goals in improving patient outcomes. Through his expertise and visionary approach, Jose Atwan is not only enhancing the oncology landscape at Merck but also making a lasting impact on the lives of patients worldwide.
